Product/Composition:- | Meloxicam tablets |
---|---|
Strength:- | 7.5 mg, 15 mg |
Form:- | Oral Tablets |
Reference Brands:- | Mobic(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Meloxicam inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis involved in pain and inflammation. Benefits include effective relief from osteoarthritis, rheumatoid arthritis, and chronic inflammatory conditions, with once-daily dosing, a favorable safety profile, and targeted anti-inflammatory effects, improving joint function and quality of life.
Meloxicam tablets are approved in the EU and US for osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis. In the EU, brands like Mobic are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data; generic options are also available. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for meloxicam tablets, ensuring adherence to European and US standards for safe, effective anti-inflammatory treatment, helping you navigate complex regulatory landscapes seamlessly.